2-(己-5-烯基)丙烷-1,3-二醇 | 102370-22-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-(己-5-烯基)丙烷-1,3-二醇
• 英文名称: 2-(hex-5-en-1-yl)propane-1,3-diol
• 英文别名: 2-(hex-5-enyl)propane-1,3-diol；2-Hex-5-enylpropane-1,3-diol
• CAS: 102370-22-9
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: SBLMDRHHYZWCPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(己-5-烯基)丙烷-1,3-二醇 在 dihydrogen hexachloroplatinate 、 正丁基锂 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 72.5h， 生成 1-diphenylphosphanyl-2-diphenylphosphanylmethyl-8-(trimethoxysilyl)octane
  参考文献：
  名称：

  Supported organometallic complexes XVI

  摘要：

  The dppp ligand 4(T-0) being provided with a T-silylfunctionalized (CH2)(6) spacer in the symmetric position of the C3 bridge is obtained by a simple three step reaction starting with 2-hydroxymethyl-1-hydroxy-7-octene (1) (Scheme 1). 1 is chlorinated to the dichloride 2 which can be hydrosilylated with HSi(OMe)(3) to give 3(T-0). Finally both chlorine atoms in 3(T-0) are exchanged by PPh2. Treatment of (COD)PdCl2 with 4(T-0) results in the formation of the T-silylfunctionalized palladium complex 5(T-0). (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0022-328x(98)00374-x
• 作为产物：
  描述：

  6-溴-1-己烯 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 32.17h， 生成 2-(己-5-烯基)丙烷-1,3-二醇
  参考文献：
  名称：

  [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
  [FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V

  摘要：

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。

  公开号：

  WO2018089355A1

文献信息

• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Catalytic activity of cationic diphospalladium(II) complexes in the alkene/CO copolymerization in organic solvents and water in dependence on the length of the alkyl chain at the phosphine ligands
  作者：Ekkehard Lindner、Markus Schmid、Joachim Wald、Joachim A. Queisser、Michael Geprägs、Peter Wegner、Christiane Nachtigal

  DOI：10.1016/s0022-328x(00)00154-6

  日期：2000.5

  analysis. In particular the water-soluble complexes 2c–k proved to be highly active in the carbon monoxide/ethene copolymerization under biphasic conditions (water–toluene). In the presence of an emulsifier and methanol as activator the catalytic activity increased by a factor of about three. Also higher olefins could be successfully incorporated into the copolymerization with CO and the terpolymerization

  一系列双膦配体CH 2（CH 2 PR 2）2（1a – x）（a – g：R =（CH 2）n OH，n = 1，3-8; h – k：R =（CH 2）n CH（CH 2 OH）2，n = 3–6；l – u：R = C n H 2 n +1，n = 1–8，10，14; v – x：R = CH（CH 3通过相应的1-烯烃的加氢磷酸化反应制备具有不同极性官能团的）2，（CH 2）2 CH（CH 3）2，（CH 2）3 CH（CH 3）2（方案1）。 H 2 P（CH 2）3 PH 2或格氏试剂与Cl 2 P（CH 2）3 PCl 2的反应。水溶性钯络合物[（R 2 P（CH 2）3 PR 2）Pd（OAc）2 ]（2a - k）是通过Pd（OAc）2与配体1a - k在乙醇-乙腈中的反应获得的。用1l – x处理PdCl 2（NCC 6 H 5）2得到二氯钯（II）络合物[（R 2 P（CH
• Heterocyclic compounds
  申请人：——

  公开号：US20030166697A1

  公开（公告）日：2003-09-04

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R 1 -Het-D-E  [1] wherein: R 1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种用于高脂血症的预防或治疗剂，其活性成分为式[1]所示的杂环化合物或其药学上可接受的盐：R1-Het-D-E [1]其中：R1为任选取代的芳基或芳香性杂环基团，Het为二价芳香性杂环基团，D为亚烷基、亚烯基、亚炔基等，E为羧基等，以及上述式[1]所示杂环化合物中的新型化合物，其具有降低血液甘油三酯、降低LDL-C、降低血糖、降低血液胰岛素、增加HDL-C或降低动脉粥样硬化指数的效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖等疾病。
• HETEROCYCLIC COMPOUNDS
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1295875A1

  公开（公告）日：2003-03-26

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1] or a pharmaceutically acceptable salt thereof:         R1―Het―D―E     [1] wherein: R1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种预防或治疗高脂血症的药物，其活性成分包括式 [1] 的杂环化合物或其药学上可接受的盐： R1-Het-D-E [1] 其中 R1为任选取代的芳基或芳香杂环基团，Het为二价芳香杂环基团，D为亚烷基、亚烯基、亚炔基或类似基团，E为羧基或类似基团，上述式[1]杂环化合物中的新型化合物，具有降血甘油三酯作用、低密度脂蛋白胆固醇（LDL-C）降低效果、血糖降低效果和血胰岛素降低效果，或高密度脂蛋白胆固醇（HDL-C）增加效果或动脉粥样硬化指数降低效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖症等。
• Heterocyclic compounds for the treatment of hyperlipidemia agents
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1634876A2

  公开（公告）日：2006-03-15

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1] or a pharmaceutically acceptable salt thereof:         R 1 -Het-D-E     [1] The preventive or therapeutic agent has a blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种预防或治疗高脂血症的药物，其活性成分包括式 [1] 的杂环化合物或其药学上可接受的盐： R 1 -Het-D-E [1] 该预防或治疗剂具有降血甘油三酯作用、降低密度脂蛋白胆固醇作用、降血糖作用和降血胰岛素作用，或增加高密度脂蛋白胆固醇作用或降低动脉粥样硬化指数作用，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖症等。